{"id":745339,"date":"2016-07-29T05:45:00","date_gmt":"2016-07-29T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/"},"modified":"2025-11-07T01:25:42","modified_gmt":"2025-11-07T06:25:42","slug":"merck-announces-second-quarter-2016-financial-results","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/","title":{"rendered":"Merck Announces Second-Quarter 2016 Financial Results"},"content":{"rendered":"<ul>\n<li>         Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of          1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange       <\/li>\n<li>         Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS          Was $0.93       <\/li>\n<li>         Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be          Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to          $3.77       <\/li>\n<li>         Advanced KEYTRUDA Development Program\n<ul>\n<li>             KEYTRUDA Demonstrated Superior Progression-Free Survival and              Overall Survival Compared to Chemotherapy in Patients with              Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)              Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study           <\/li>\n<li>             Merck Received Positive Opinion from Committee for Medicinal              Products for Human Use of the European Medicines Agency for              KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in              Patients Whose Tumors Express PD-L1           <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced financial results for the second quarter of 2016.\n    <\/p>\n<p>\n      \u201cOur results this quarter reflect our strategic focus on key launches,<br \/>\n      including KEYTRUDA and ZEPATIER, as well as our priority inline<br \/>\n      programs,\u201d said Kenneth C. Frazier, chairman and chief executive<br \/>\n      officer, Merck. \u201cWe remain committed to advancing our pipeline,<br \/>\n      delivering a balanced and differentiated portfolio, and achieving<br \/>\n      long-term, sustainable growth.\u201d\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">\n            <b>Financial Summary<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          $ in millions, except EPS amounts\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc\" colspan=\"3\">\n          <b>Second Quarter<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>2016<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>2015<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Sales\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $9,844\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $9,785\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          GAAP EPS\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0.43\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0.24\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">\n            Non-GAAP EPS that excludes items listed below<sup>1<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0.93\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0.86\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">\n            GAAP net income<sup>2<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,205\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          687\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Non-GAAP net income that excludes items listed below<sup>1,2<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2,587\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          2,441\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      Worldwide sales were $9.8 billion for the second quarter of 2016, an<br \/>\n      increase of 1 percent compared with the second quarter of 2015,<br \/>\n      including a 2 percent negative impact from foreign exchange.\n    <\/p>\n<p>\n      GAAP (generally accepted accounting principles) earnings per share (EPS)<br \/>\n      were $0.43 for the second quarter. Non-GAAP EPS of $0.93 for the second<br \/>\n      quarter excludes acquisition- and divestiture-related costs and<br \/>\n      restructuring costs.\n    <\/p>\n<p>\n      <b>Pipeline Highlights<\/b>\n    <\/p>\n<p>\n      In the second quarter of 2016, the company advanced its late-stage<br \/>\n      pipeline in multiple priority areas and executed on key launches,<br \/>\n      including KEYTRUDA (pembrolizumab), an anti-PD-1 therapy for the<br \/>\n      treatment of metastatic NSCLC in previously treated patients whose<br \/>\n      tumors express PD-L1, as well as advanced melanoma; and ZEPATIER<br \/>\n      (elbasvir and grazoprevir), a once-daily, fixed-dose combination tablet<br \/>\n      for the treatment of adult patients with chronic hepatitis C virus (HCV)<br \/>\n      genotype (GT) 1 or GT4 infection, with or without ribavirin.\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        The company advanced its clinical development program for KEYTRUDA.<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            The company <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmercks-keytruda%25C2%25A0pembrolizumab-demonstrates-superior-progression-free-&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=announced&amp;index=1&amp;md5=0ff6e39cf30e5d4ad1b332d61dbba042\" rel=\"nofollow\">announced<\/a><br \/>\n            topline results from the KEYNOTE-024 trial investigating the use<br \/>\n            of KEYTRUDA in patients with previously untreated advanced NSCLC<br \/>\n            whose tumors expressed high levels of PD-L1 (tumor proportion<br \/>\n            score of 50 percent or more).<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n                In this study, KEYTRUDA was superior compared to chemotherapy<br \/>\n                for the primary endpoint of progression-free survival and the<br \/>\n                secondary endpoint of overall survival.\n              <\/li>\n<li class=\"bwlistitemmargb\">\n                Based on these results, an independent Data Monitoring<br \/>\n                Committee recommended that the trial be stopped and that<br \/>\n                patients receiving chemotherapy in KEYNOTE-024 be offered the<br \/>\n                opportunity to receive KEYTRUDA.\n              <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n            The U.S. Food and Drug Administration (FDA) <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Ffda-accepts-supplemental-biologics-license-application-sbla-keytrud-2&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=accepted&amp;index=2&amp;md5=19f33563f7d3dcea4bd9ccb8c2a0d110\" rel=\"nofollow\">accepted<\/a><br \/>\n            for review a supplemental Biologics License Application for<br \/>\n            KEYTRUDA for the treatment of patients with recurrent or<br \/>\n            metastatic head and neck squamous cell carcinoma with disease<br \/>\n            progression on or after platinum-containing chemotherapy. The FDA<br \/>\n            granted Priority Review with a PDUFA action date of Aug. 9, 2016.\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            The Committee for Medicinal Products for Human Use (CHMP) of the<br \/>\n            European Medicines Agency (EMA) <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmerck-receives-chmp-positive-opinion-keytruda-pembrolizumab-treatment&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=adopted&amp;index=3&amp;md5=a8527f1d8f9dadecbd4bad861366f769\" rel=\"nofollow\">adopted<\/a><br \/>\n            a positive opinion recommending approval of KEYTRUDA<sup> <\/sup>for<br \/>\n            the treatment of locally advanced or metastatic NSCLC in adults<br \/>\n            whose tumors express PD-L1 and who have received at least one<br \/>\n            prior chemotherapy regimen.\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            At the 52<sup>nd<\/sup> Annual Meeting of the American Society of<br \/>\n            Clinical Oncology in June, data <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fnew-keytruda-pembrolizumab-data-2016-asco-annual-meeting-includes-thr&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=were+presented&amp;index=4&amp;md5=8b971fff0284049ab432e91f56bf76f8\" rel=\"nofollow\">were<br \/>\n            presented<\/a> evaluating the use of KEYTRUDA as a monotherapy and<br \/>\n            in combination with other therapies in more than 15 different<br \/>\n            cancers, including melanoma, NSCLC, head and neck cancer,<br \/>\n            classical Hodgkin lymphoma, multiple myeloma, colorectal cancer<br \/>\n            and esophageal cancer. Data evaluating KEYTRUDA in new tumor types<br \/>\n            were presented for the first time in cervical, endometrial,<br \/>\n            pancreatic, salivary and thyroid cancers.\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            The KEYTRUDA research program includes more than 300 clinical<br \/>\n            trials evaluating KEYTRUDA across more than 30 tumor types. To<br \/>\n            date, clinical activity has been shown in more than 20 tumor types.\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Last week, the European Commission approved ZEPATIER for the treatment<br \/>\n        of chronic HCV in adult patients, allowing marketing of ZEPATIER in<br \/>\n        all 28 European Union (EU) member states. The company continues to<br \/>\n        work to supply the EU market, with product launches estimated to begin<br \/>\n        between the fourth quarter of 2016 and the first quarter of 2017.<br \/>\n        Product launches are expected to continue across the EU through 2017.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        At the 76<sup>th<\/sup> Scientific Sessions of the American Diabetes<br \/>\n        Association in June, Merck and Pfizer <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fcorporate-news%2Fmerck-and-pfizer-announce-two-pivotal-phase-3-studies-ertugliflozin-inve&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=announced&amp;index=5&amp;md5=af21d3206051b7bf91f31d115da4dd4e\" rel=\"nofollow\">announced<\/a><br \/>\n        that two pivotal Phase 3 studies of ertugliflozin, an investigational<br \/>\n        oral SGLT-2 inhibitor for the treatment of patients with type 2<br \/>\n        diabetes, met their primary endpoints, showing significant reductions<br \/>\n        in A1C (a measure of average blood glucose). The companies continue to<br \/>\n        expect to submit New Drug Applications to the FDA for ertugliflozin as<br \/>\n        a monotherapy and two fixed-dose combination tablets (ertugliflozin<br \/>\n        plus JANUVIA [sitagliptin], and ertugliflozin plus metformin) by the<br \/>\n        end of 2016.\n      <\/li>\n<\/ul>\n<p>\n      <b>Business Development Highlights<\/b>\n    <\/p>\n<p>\n      Business development remains a critical component of Merck\u2019s strategy,<br \/>\n      and the company is actively engaged in seeking external opportunities to<br \/>\n      complement and strengthen its pipeline and portfolio. The company<br \/>\n      recently engaged in the following scientific collaborations and<br \/>\n      acquisitions:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Earlier this week, the company completed its <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fcorporate-news%2Fmerck-acquire-afferent-pharmaceuticals&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=acquisition&amp;index=6&amp;md5=b8927bb4bdeaf9d578c59e0716d0817b\" rel=\"nofollow\">acquisition<\/a><br \/>\n        of Afferent Pharmaceuticals, a leader in the development of<br \/>\n        investigational therapeutic candidates for the treatment of common,<br \/>\n        poorly managed, neurogenic conditions, such as chronic cough.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The company <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmerck-and-moderna-announce-strategic-collaboration-advance-novel-mrna&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=announced&amp;index=7&amp;md5=0c284285239187a94556f6bacc407a3b\" rel=\"nofollow\">announced<\/a><br \/>\n        a new collaboration with Moderna Therapeutics to develop and<br \/>\n        commercialize personalized cancer vaccines, combining KEYTRUDA and<br \/>\n        Moderna\u2019s messenger-RNA technology.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Merck Animal Health <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fcorporate-news%2Fmerck-animal-health-announces-agreement-acquire-controlling-interest-bra&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=announced&amp;index=8&amp;md5=384f3948ff29bd89026d0f4113ffe065\" rel=\"nofollow\">announced<\/a><br \/>\n        it will acquire a controlling interest in Vall\u00e9e S.A., a privately<br \/>\n        held producer of animal health products in Brazil with a portfolio of<br \/>\n        more than 100 products for livestock, horses and companion animals.\n      <\/li>\n<\/ul>\n<p>\n      <b>Second-Quarter Revenue Performance<\/b>\n    <\/p>\n<p>\n      The following table reflects sales of the company\u2019s top pharmaceutical<br \/>\n      products, as well as total sales of Animal Health products.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          $ in millions\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc\" colspan=\"3\">\n          <b>Second Quarter<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc\" rowspan=\"2\">\n          <b>Change<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\" rowspan=\"2\">\n          <b>Change<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>Ex-Exchange<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>2016<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>2015<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Total Sales\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $9,844\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $9,785\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Pharmaceutical\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          8,700\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          8,564\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          JANUVIA \/ JANUMET\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,634\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,598\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          ZETIA \/ VYTORIN\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          994\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          955\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          4%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          4%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          GARDASIL \/ GARDASIL 9\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          393\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          427\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -8%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -7%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          PROQUAD \/ M-M-R II \/ VARIVAX\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          383\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          358\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          7%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          10%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          CUBICIN\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          357\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          293\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          22%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          22%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          REMICADE\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          339\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          455\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -26%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -26%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          ISENTRESS\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          338\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          375\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -10%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -9%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          KEYTRUDA\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          314\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          110\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          *\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          *\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Animal Health\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          898\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          840\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          7%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          10%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Other Revenues\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          246\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          381\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -36%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          -2%\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignr\">\n<p class=\"bwcellpmargin\">\n            * &gt;100%\n          <\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n      <b>Pharmaceutical Revenue<\/b>\n    <\/p>\n<p>\n      Second-quarter pharmaceutical sales increased 2 percent to $8.7 billion,<br \/>\n      reflecting higher sales in oncology, hospital acute care, the<br \/>\n      cardiovascular franchise and vaccines.\n    <\/p>\n<p>\n      Growth in oncology was driven by higher sales of KEYTRUDA as the company<br \/>\n      continues to launch the product with new indications globally.\n    <\/p>\n<p>\n      Growth in hospital acute care reflects higher sales of CUBICIN<br \/>\n      (daptomycin for injection), an I.V. antibiotic, partially due to price<br \/>\n      increases in the United States, and the U.S. launch of BRIDION<br \/>\n      (sugammadex) Injection 100 mg\/mL, an agent for the reversal of<br \/>\n      neuromuscular blockade induced by rocuronium bromide or vecuronium<br \/>\n      bromide in adults undergoing surgery. In June 2016, the company lost<br \/>\n      U.S. patent protection for CUBICIN, and, going forward, the company<br \/>\n      anticipates a significant decline in CUBICIN sales.\n    <\/p>\n<p>\n      Higher sales in the cardiovascular portfolio were primarily driven by an<br \/>\n      increase in sales of ZETIA (ezetimibe), a medicine for lowering LDL<br \/>\n      cholesterol, largely due to price increases in the United States, and<br \/>\n      ADEMPAS (riociguat), a medicine for treating pulmonary arterial<br \/>\n      hypertension and chronic thromboembolic pulmonary hypertension, which<br \/>\n      the company is now promoting and distributing in Europe.\n    <\/p>\n<p>\n      Growth in vaccines resulted largely from higher sales of pediatric<br \/>\n      vaccines, partially offset by lower sales in the franchise of GARDASIL 9<br \/>\n      (Human Papillomavirus 9-valent Vaccine, Recombinant) and GARDASIL [Human<br \/>\n      Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine,<br \/>\n      Recombinant], vaccines to prevent cancers and other diseases caused by<br \/>\n      HPV, due to the timing of public sector purchases.\n    <\/p>\n<p>\n      Pharmaceutical sales growth also reflects the launch of ZEPATIER, which<br \/>\n      had sales of $112 million in the quarter.\n    <\/p>\n<p>\n      Second-quarter pharmaceutical sales reflect a decline in REMICADE<br \/>\n      (infliximab), a treatment for inflammatory diseases, due to the impact<br \/>\n      of biosimilar competition in the company\u2019s marketing territories in<br \/>\n      Europe. Pharmaceutical sales also reflect a decrease in sales of NASONEX<br \/>\n      (mometasone furoate monohydrate), an inhaled nasal corticosteroid for<br \/>\n      the treatment of nasal allergy symptoms, due to loss of exclusivity in<br \/>\n      the United States.\n    <\/p>\n<p>\n      <b>Animal Health Revenue<\/b>\n    <\/p>\n<p>\n      Animal Health sales totaled $898 million for the second quarter of 2016,<br \/>\n      an increase of 7 percent compared with the second quarter of 2015,<br \/>\n      including a 3 percent negative impact from foreign exchange. Excluding<br \/>\n      the impact of exchange, sales across all species grew, particularly in<br \/>\n      products for companion animals, led by BRAVECTO (fluralaner), a chewable<br \/>\n      tablet that kills fleas and ticks in dogs for up to 12 weeks.\n    <\/p>\n<p>\n      In the second quarter, the company <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fanimal-health%2Fmsd-animal-health-receives-marketing-approval-european-medicines-agency-b&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=received&amp;index=9&amp;md5=c0ef35e29c440113a2920bcaf036f36c\" rel=\"nofollow\">received<\/a><br \/>\n      marketing approval from the EMA for BRAVECTO Spot-On Solution for cats<br \/>\n      and dogs; last week, the company <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fcorporate-news%2Fmerck-animal-health-receives-fda-approval-bravecto-fluralaner-topical-so&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=received&amp;index=10&amp;md5=afcb955da2103399e8182b0cde3e2a13\" rel=\"nofollow\">received<\/a><br \/>\n      approval in the United States to market the product under the tradename<br \/>\n      BRAVECTO Topical (fluralaner topical solution) for cats and dogs.\n    <\/p>\n<p>\n      <b>Second-Quarter Expense, EPS and Related Information<\/b>\n    <\/p>\n<p>\n      The tables below present selected expense information.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          $ in millions\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">\n            \u00a0\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>GAAP<\/b>\n          <\/p>\n<\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">\n            <b>Acquisition-<\/b><br \/>\n<br \/>\n<b> and Divestiture-<\/b><br \/>\n<br \/>\n<b>Related<br \/>\n            Costs<\/b><br \/>\n<sup>3<\/sup>\n          <\/p>\n<\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">\n            <b>Restructuring<\/b><br \/>\n<br \/>\n<b> Costs<\/b>\n          <\/p>\n<\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">\n            \u00a0\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Non-GAAP<\/b><br \/>\n<sup>1<\/sup>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          <b>Second-Quarter 2016<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl\">\n          Materials and production\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $3,578\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $1,120\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $66\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $2,392\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl\">\n          Marketing and administrative\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,458\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          18\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          87\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,353\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl\">\n          Research and development\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,151\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          207\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          64\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,880\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl\">\n          Restructuring costs\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          \u2013\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          \u2013\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl\">\n          <b>Second-Quarter 2015<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl\">\n          Materials and production\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $3,754\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $1,241\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $105\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $2,408\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl\">\n          Marketing and administrative\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,624\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          136\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          17\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,471\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl\">\n          Research and development\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,670\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          71\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          15\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,584\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          191\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          \u2013\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          191\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          \u2013\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      <b>GAAP Expense, EPS and Related Information<\/b>\n    <\/p>\n<p>\n      On a GAAP basis, the gross margin was 63.7 percent for the second<br \/>\n      quarter of 2016 compared to 61.6 percent for the second quarter of 2015.<br \/>\n      The increase for the second quarter of 2016 reflects the favorable<br \/>\n      impacts of foreign exchange; product mix; lower acquisition- and<br \/>\n      divestiture-related costs; and lower restructuring costs. Acquisition-<br \/>\n      and divestiture-related costs and restructuring costs negatively<br \/>\n      affected gross margin by 12.0 and 13.8 percentage points for the second<br \/>\n      quarters of 2016 and 2015, respectively.\n    <\/p>\n<p>\n      Marketing and administrative expenses were $2.5 billion in the second<br \/>\n      quarter of 2016, a 6 percent decrease compared to the second quarter of<br \/>\n      2015. The decline reflects lower acquisition- and divestiture-related<br \/>\n      costs, as well as lower administrative costs, such as legal defense<br \/>\n      reserves, partially offset by higher restructuring costs.\n    <\/p>\n<p>\n      Research and development (R&amp;D) expenses were $2.2 billion in the second<br \/>\n      quarter of 2016, a 29 percent increase compared to the second quarter of<br \/>\n      2015. The increase primarily reflects higher licensing costs, increased<br \/>\n      clinical development spending and intangible asset impairment charges.\n    <\/p>\n<p>\n      Other (income) expense, net, was $19 million of expense in the second<br \/>\n      quarter of 2016 compared to $739 million of expense in the second<br \/>\n      quarter of 2015. The second quarter of 2015 includes foreign exchange<br \/>\n      losses of $715 million related to the devaluation of the company\u2019s net<br \/>\n      monetary assets in Venezuela.\n    <\/p>\n<p>\n      GAAP EPS was $0.43 for the second quarter of 2016 compared with $0.24<br \/>\n      for the second quarter of 2015.\n    <\/p>\n<p>\n      <b>Non-GAAP Expense, EPS and Related Information<\/b>\n    <\/p>\n<p>\n      The non-GAAP gross margin was 75.7 percent for the second quarter of<br \/>\n      2016 compared to 75.4 percent for the second quarter of 2015. The<br \/>\n      increase for the second quarter of 2016 reflects the favorable impacts<br \/>\n      of foreign exchange and product mix.\n    <\/p>\n<p>\n      Non-GAAP marketing and administrative expenses were $2.4 billion in the<br \/>\n      second quarter of 2016, a 5 percent decline compared to the second<br \/>\n      quarter of 2015. The decline reflects lower administrative costs, such<br \/>\n      as legal defense reserves.\n    <\/p>\n<p>\n      Non-GAAP R&amp;D expenses were $1.9 billion in the second quarter of 2016, a<br \/>\n      19 percent increase compared to the second quarter of 2015. The increase<br \/>\n      primarily reflects higher licensing costs and increased clinical<br \/>\n      development spending.\n    <\/p>\n<p>\n      Non-GAAP EPS was $0.93 for the second quarter of 2016 compared with<br \/>\n      $0.86 for the second quarter of 2015.\n    <\/p>\n<p>\n      A reconciliation of GAAP to non-GAAP net income and EPS is provided in<br \/>\n      the table that follows. Year-to-date results can be found in the<br \/>\n      attached tables.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          $ in millions, except EPS amounts\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc\" colspan=\"3\">\n          <b>Second Quarter<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>2016<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>2015<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          <b>EPS<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          GAAP EPS\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $0.43\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $0.24\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">\n            Difference<sup>4<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0.50\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0.62\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">\n            Non-GAAP EPS that excludes items listed below<sup>1<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $0.93\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $0.86\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          <b>Net Income<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          GAAP net income<sup>2<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $1,205\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $687\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Difference\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,382\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,754\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Non-GAAP net income that excludes items listed below<sup>1,2<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $2,587\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $2,441\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          <b>Decrease (Increase) in Net Income Due to Excluded Items:<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          Acquisition- and divestiture-related costs<sup>3<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $ 1,345\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $1,448\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          Restructuring costs\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          351\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          328\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          Foreign exchange losses related to Venezuela\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          \u2013\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          715\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Net decrease (increase) in income before taxes\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,696\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,491\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">\n            Income tax (benefit) expense<sup>5<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (314)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (737)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Decrease (increase) in net income\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $ 1,382\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $1,754\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      <b>Financial Outlook<\/b>\n    <\/p>\n<p>\n      Merck has lowered its full-year 2016 GAAP EPS range to be between $1.98<br \/>\n      and $2.08, reflecting the impact of intangible asset impairment charges<br \/>\n      and higher restructuring costs incurred in the second quarter of 2016.<br \/>\n      The company has raised the bottom end of its full-year 2016 non-GAAP EPS<br \/>\n      range and is now targeting a range of $3.67 to $3.77, including an<br \/>\n      approximately 1 percent negative impact from foreign exchange at current<br \/>\n      exchange rates. The non-GAAP range excludes acquisition- and<br \/>\n      divestiture-related costs and costs related to restructuring programs.\n    <\/p>\n<p>\n      Merck has narrowed its full-year 2016 revenue range to be between $39.1<br \/>\n      billion and $40.1 billion, including an approximately 2 percent negative<br \/>\n      impact from foreign exchange at current exchange rates.\n    <\/p>\n<p>\n      The following table summarizes the company\u2019s 2016 financial guidance.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          <b>GAAP<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          <b>Non-GAAP<\/b><br \/>\n<sup>1<\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Revenue\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          $39.1 to $40.1 billion\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          $39.1 to $40.1 billion**\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Marketing and administrative expenses\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          Lower than 2015\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          Lower than 2015\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          R&amp;D expenses\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          Higher than 2015\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          Higher than 2015\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Effective tax rate\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          26.0% to 27.0%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          21.5% to 22.5%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          EPS\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr bwsinglebottom\">\n          $1.98 to $2.08\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr bwsinglebottom\">\n          $3.67 to $3.77\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignr\" colspan=\"5\">\n<p class=\"bwcellpmargin\">\n            ** The company does not have any non-GAAP adjustments to revenue.\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\">\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      A reconciliation of anticipated 2016 GAAP EPS to non-GAAP EPS and the<br \/>\n      items excluded from non-GAAP EPS are provided in the table below.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">\n            $ in millions, except EPS amounts\n          <\/p>\n<\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          <b>Full-Year 2016<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          GAAP EPS\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          $1.98 to $2.08\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Difference<sup>4<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1.69\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Non-GAAP EPS that excludes items listed below<sup>1<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignr\">\n          $3.67 to $3.77\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          Acquisition- and divestiture-related costs\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $4,750\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignb bwalignl\">\n          Restructuring costs\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          900\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Net decrease (increase) in income before taxes\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5,650\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl\">\n          Estimated income tax (benefit) expense\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (955)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Decrease (increase) in net income\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $4,695\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      The expected full-year 2016 GAAP effective tax rate of 26.0 to 27.0<br \/>\n      percent reflects an unfavorable impact of approximately 4.5 percentage<br \/>\n      points from the above items.\n    <\/p>\n<p>\n      <b>Total Employees<\/b>\n    <\/p>\n<p>\n      As of June 30, 2016, Merck had approximately 68,000 employees worldwide.\n    <\/p>\n<p>\n      <b>Earnings Conference Call<\/b>\n    <\/p>\n<p>\n      Investors, journalists and the general public may access a live audio<br \/>\n      webcast of the call today at 8:00 a.m. EDT on Merck\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.merck.com%2Finvestors%2Fwebcasts-and-presentations%2Fdefault.aspx&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.merck.com%2Finvestors%2Fwebcasts-and-presentations%2Fdefault.aspx&amp;index=11&amp;md5=28f76ba3706ed85474ad4d7e2414a296\" rel=\"nofollow\">http:\/\/investors.merck.com\/investors\/webcasts-and-presentations\/default.aspx<\/a>.<br \/>\n      Institutional investors and analysts can participate in the call by<br \/>\n      dialing (706) 758-9927 or (877) 381-5782 and using ID code number<br \/>\n      34462082. Members of the media are invited to monitor the call by<br \/>\n      dialing (706) 758-9928 or (800) 399-7917 and using ID code number<br \/>\n      34462082. Journalists who wish to ask questions are requested to contact<br \/>\n      a member of Merck\u2019s Media Relations team at the conclusion of the call.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies and animal health products, we work with customers and operate<br \/>\n      in more than 140 countries to deliver innovative health solutions. We<br \/>\n      also demonstrate our commitment to increasing access to health care<br \/>\n      through far-reaching policies, programs and partnerships. For more<br \/>\n      information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=12&amp;md5=9132e79e6e3507b475c1c55da6528db7\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=Twitter&amp;index=13&amp;md5=27927ab86fe1a63a23bcb76cde3e8fff\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=Facebook&amp;index=14&amp;md5=d9cc67e0fed1772c588d95b72d365295\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=YouTube&amp;index=15&amp;md5=2ff689ba0fd0260dc3f918f991d2c5d1\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=16&amp;md5=2415223ce7113462c69f6240701feb0a\" rel=\"nofollow\">LinkedIn<\/a>.<br \/>\n      You can also follow our Twitter conversation at $MRK.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51391971&amp;newsitemid=20160729005318&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=17&amp;md5=ece0429180dfe3ef32a4b047491d87b1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Merck is providing certain 2016 and 2015 non-GAAP<br \/>\n      information that excludes certain items because of the nature of these<br \/>\n      items and the impact they have on the analysis of underlying business<br \/>\n      performance and trends. Management believes that providing this<br \/>\n      information enhances investors\u2019 understanding of the company\u2019s<br \/>\n      performance. Management uses these measures internally for planning and<br \/>\n      forecasting purposes and to measure the performance of the company along<br \/>\n      with other metrics. Senior management\u2019s annual compensation is derived<br \/>\n      in part using non-GAAP income and non-GAAP EPS. This information should<br \/>\n      be considered in addition to, but not as a substitute for or superior<br \/>\n      to, information prepared in accordance with GAAP. For a description of<br \/>\n      the items, see Table 2a attached to this release.\n    <\/p>\n<p>\n      <sup>2 <\/sup>Net income attributable to Merck &amp; Co., Inc.\n    <\/p>\n<p>\n      <sup>3 <\/sup>Includes expenses for the amortization of intangible assets<br \/>\n      and purchase accounting adjustments to inventories recognized as a<br \/>\n      result of acquisitions, intangible asset impairment charges and expense<br \/>\n      or income related to changes in the estimated fair value measurement of<br \/>\n      contingent consideration. Also includes integration, transaction and<br \/>\n      certain other costs related to business acquisitions and divestitures.\n    <\/p>\n<p>\n      <sup>4 <\/sup>Represents the difference between calculated GAAP EPS and<br \/>\n      calculated non-GAAP EPS, which may be different than the amount<br \/>\n      calculated by dividing the impact of the excluded items by the<br \/>\n      weighted-average shares for the period.\n    <\/p>\n<p>\n      <sup>5 <\/sup>Includes the estimated tax impact on the reconciling items.<br \/>\n      In addition, amount for the second quarter of 2015 includes a net<br \/>\n      benefit of $370 million related to the settlement of certain federal<br \/>\n      income tax issues.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td colspan=\"17\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"17\">\n          <b>MERCK &amp; CO., INC.<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"17\">\n          <b>CONSOLIDATED STATEMENT OF INCOME &#8211; GAAP<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"17\">\n          <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"17\">\n          <b>(UNAUDITED)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"17\">\n          <b>Table 1<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\" rowspan=\"2\">\n          <b>GAAP<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"3\">\n          <b>% Change<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\" rowspan=\"2\">\n          <b>GAAP<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"3\">\n          <b>% Change<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>2Q16<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>2Q15<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">\n            <b>June YTD<\/b><br \/>\n<br \/>\n<b> 2016<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">\n            <b>June YTD<\/b><br \/>\n<br \/>\n<b> 2015<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Sales\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          9,844\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          9,785\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          1%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          19,156\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          19,210\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          &#8212;\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Costs, Expenses and Other\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignt bwalignl\">\n          Materials and production <sup>(1)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,578\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,754\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          -5%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          7,150\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          7,323\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          -2%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignt bwalignl\">\n          Marketing and administrative <sup>(1)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,458\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,624\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          -6%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          4,776\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5,226\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          -9%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignt bwalignl\">\n          Research and development <sup>(1)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,151\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,670\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          29%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,810\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,407\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          12%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignt bwalignl\">\n          Restructuring costs <sup>(2)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          191\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          -30%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          225\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          273\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          -18%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignt bwalignl\">\n          Other (income) expense, net <sup>(1) (3)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          19\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          739\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          -97%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          67\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          793\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          -92%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Income Before Taxes\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,504\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          807\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          86%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,128\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,188\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          43%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Taxes on Income\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          295\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          119\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          789\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          542\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Net Income\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,209\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          688\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          76%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,339\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,646\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          42%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Less: Net Income Attributable to Noncontrolling Interests\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          4\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          9\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          7\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Net Income Attributable to Merck &amp; Co., Inc.\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,205\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          687\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          75%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,330\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,639\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          42%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">\n          Earnings per Common Share Assuming Dilution\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.43\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.24\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          79%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.83\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.57\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          46%\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Average Shares Outstanding Assuming Dilution\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,789\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,850\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,792\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,856\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">\n          Tax Rate <sup>(4)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          19.6%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          14.7%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          25.2%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          24.8%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          (1) Amounts include the impact of acquisition and<br \/>\n          divestiture-related costs, restructuring costs and certain other<br \/>\n          items. See accompanying tables for details.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          (2) Represents separation and other related costs associated with<br \/>\n          restructuring activities under the company&#8217;s formal restructuring<br \/>\n          programs.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          (3) Other (income) expense, net in the second quarter and first six<br \/>\n          months of 2016 includes a $115 million gain related to settlement of<br \/>\n          certain patent litigation. Other (income) expense, net in the second<br \/>\n          quarter and first six months of 2015 includes foreign exchange<br \/>\n          losses of $715 million to devalue the company&#8217;s net monetary assets<br \/>\n          in Venezuela.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          (4) The effective income tax rates for the second quarter and first<br \/>\n          six months of 2015 reflect a net benefit of $370 million related to<br \/>\n          the settlement of certain federal income tax issues, partially<br \/>\n          offset by the unfavorable impact of non-deductible foreign exchange<br \/>\n          losses recorded in connection with the devaluation of the company&#8217;s<br \/>\n          net monetary assets in Venezuela.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td colspan=\"15\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>MERCK &amp; CO., INC.<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>GAAP TO NON-GAAP RECONCILIATION<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>SECOND QUARTER 2016<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>(UNAUDITED)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>Table 2a<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>GAAP<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Acquisition and<\/b><br \/>\n<br \/>\n<b> Divestiture-<\/b><br \/>\n<br \/>\n<b>Related<br \/>\n            Costs <\/b><br \/>\n<sup><br \/>\n<b>(1)<\/b><br \/>\n<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Restructuring<\/b><br \/>\n<br \/>\n<b> Costs <\/b><br \/>\n<sup><br \/>\n<b>(2)<\/b><br \/>\n<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Adjustment<\/b><br \/>\n<br \/>\n<b> Subtotal<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>Non-GAAP<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Materials and production\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>3,578<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,120\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          66\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,186\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,392\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Marketing and administrative\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>2,458<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          18\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          87\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          105\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,353\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Research and development\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>2,151<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          207\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          64\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          271\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,880\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Restructuring costs\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>134<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          &#8211;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Income Before Taxes\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,504<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,345)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (351)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,696)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,200\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Tax Provision (Benefit)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>295<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (235)\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <sup>(3)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (79)\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <sup>(3)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (314)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          609\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Net Income\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,209<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,110)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (272)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,382)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,591\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Net Income Attributable to Merck &amp; Co., Inc.\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,205<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,110)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (272)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (1,382)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,587\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">\n          Earnings per Common Share Assuming Dilution\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>0.43<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (0.40)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (0.10)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (0.50)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          0.93\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">\n          Tax Rate\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>19.6%<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          19.0%\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Only the line items that are affected by non-GAAP adjustments are<br \/>\n          shown.\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"2\">\n          Merck is providing non-GAAP information that excludes certain items<br \/>\n          because of the nature of these items and the impact they have on the<br \/>\n          analysis of underlying business performance and trends. Management<br \/>\n          believes that providing this information enhances investors&#8217;<br \/>\n          understanding of the company&#8217;s performance. Management uses this<br \/>\n          information internally for planning and forecasting purposes and to<br \/>\n          measure the performance of the company along with other metrics.<br \/>\n          Senior management&#8217;s annual compensation is derived in part using<br \/>\n          non-GAAP income and non-GAAP EPS. This information should be<br \/>\n          considered in addition to, but not as a substitute for or superior<br \/>\n          to, information prepared in accordance with GAAP.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"2\">\n          (1) Amounts included in materials and production costs reflect $1.0<br \/>\n          billion of expenses for the amortization of intangible assets<br \/>\n          recognized as a result of acquisitions, as well as $95 million of<br \/>\n          impairment charges on product intangibles. Amounts included in<br \/>\n          marketing and administrative expenses reflect integration,<br \/>\n          transaction and certain other costs related to business<br \/>\n          acquisitions, including severance costs which are not part of the<br \/>\n          company&#8217;s formal restructuring programs, as well as transaction and<br \/>\n          certain other costs related to divestitures. Amounts included in<br \/>\n          research and development expenses primarily reflect in-process<br \/>\n          research and development (&#8220;IPR&amp;D&#8221;) impairment charges.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"2\">\n          (2) Amounts primarily include employee separation costs and<br \/>\n          accelerated depreciation associated with facilities to be closed or<br \/>\n          divested related to activities under the company&#8217;s formal<br \/>\n          restructuring programs.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"2\">\n          (3) Represents the estimated tax impact on the reconciling items,<br \/>\n          based on applying the statutory rate of the originating territory of<br \/>\n          the non-GAAP adjustments.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td colspan=\"15\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>MERCK &amp; CO., INC.<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>GAAP TO NON-GAAP RECONCILIATION<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>SIX MONTHS ENDED JUNE 30, 2016<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>(UNAUDITED)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"15\">\n          <b>Table 2b<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>GAAP<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Acquisition and<\/b><br \/>\n<br \/>\n<b> Divestiture-<\/b><br \/>\n<br \/>\n<b>Related<br \/>\n            Costs <\/b><br \/>\n<sup><br \/>\n<b>(1)<\/b><br \/>\n<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Restructuring<\/b><br \/>\n<br \/>\n<b> Costs <\/b><br \/>\n<sup><br \/>\n<b>(2)<\/b><br \/>\n<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Adjustment<\/b><br \/>\n<br \/>\n<b> Subtotal<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>Non-GAAP<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Materials and production\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>7,150<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,506\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          113\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,619\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          4,531\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Marketing and administrative\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>4,776<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          20\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          90\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          110\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          4,666\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Research and development\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>3,810<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          242\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          119\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          361\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,449\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Restructuring costs\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>225<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          225\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          225\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          &#8211;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Income Before Taxes\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>3,128<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (2,768)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (547)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (3,315)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          6,443\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Tax Provision (Benefit)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>789<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (444)\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <sup>(3)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (122)\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <sup>(3)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (566)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,355\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Net Income\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>2,339<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (2,324)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (425)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (2,749)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5,088\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Net Income Attributable to Merck &amp; Co., Inc.\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>2,330<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (2,324)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (425)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (2,749)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5,079\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">\n          Earnings per Common Share Assuming Dilution\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>0.83<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (0.84)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (0.15)\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          (0.99)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          $\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          1.82\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">\n          Tax Rate\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>25.2%<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          21.0%\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Only the line items that are affected by non-GAAP adjustments are<br \/>\n          shown.\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"2\">\n          Merck is providing non-GAAP information that excludes certain items<br \/>\n          because of the nature of these items and the impact they have on the<br \/>\n          analysis of underlying business performance and trends. Management<br \/>\n          believes that providing this information enhances investors&#8217;<br \/>\n          understanding of the company&#8217;s performance. Management uses this<br \/>\n          information internally for planning and forecasting purposes and to<br \/>\n          measure the performance of the company along with other metrics.<br \/>\n          Senior management&#8217;s annual compensation is derived in part using<br \/>\n          non-GAAP income and non-GAAP EPS. This information should be<br \/>\n          considered in addition to, but not as a substitute for or superior<br \/>\n          to, information prepared in accordance with GAAP.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"2\">\n          (1) Amounts included in materials and production costs reflect $2.1<br \/>\n          billion of expenses for the amortization of intangible assets<br \/>\n          recognized as a result of acquisitions, as well as $347 million of<br \/>\n          impairment charges on product intangibles. Amounts included in<br \/>\n          marketing and administrative expenses reflect integration,<br \/>\n          transaction and certain other costs related to business<br \/>\n          acquisitions, including severance costs which are not part of the<br \/>\n          company&#8217;s formal restructuring programs, as well as transaction and<br \/>\n          certain other costs related to divestitures. Amounts included in<br \/>\n          research and development expenses primarily reflect in-process<br \/>\n          research and development (&#8220;IPR&amp;D&#8221;) impairment charges.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"2\">\n          (2) Amounts primarily include employee separation costs and<br \/>\n          accelerated depreciation associated with facilities to be closed or<br \/>\n          divested related to activities under the company&#8217;s formal<br \/>\n          restructuring programs.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"2\">\n          (3) Represents the estimated tax impact on the reconciling items,<br \/>\n          based on applying the statutory rate of the originating territory of<br \/>\n          the non-GAAP adjustments.\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"32\">\n          <b>MERCK &amp; CO., INC.<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"32\">\n          <b>FRANCHISE \/ KEY PRODUCT SALES<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"32\">\n          <b>(AMOUNTS IN MILLIONS)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"32\">\n          <b>Table 3<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"32\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"8\">\n          <b>2016<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"17\">\n          <b>2015<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"3\">\n          <b>% Change<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>1Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>2Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>June YTD<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>1Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>2Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>June YTD<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>3Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>4Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n          <b>FY<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>2Q<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>June YTD<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1  bwvertalignt bwalignl\">\n          <b>TOTAL SALES<\/b><br \/>\n<sup><br \/>\n<b>(1)<\/b><br \/>\n<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>9,312<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>9,844<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>19,156<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>9,425<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>9,785<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>19,210<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>10,073<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>10,215<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>$<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>39,498<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>1<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>0<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignt bwalignl\">\n          <b>PHARMACEUTICAL<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,104<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,700<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>16,804<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,266<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,564<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>16,830<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>8,925<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>9,027<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>34,782<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>2<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>0<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">\n          <b>Primary Care and Women&#8217;s Health<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          Cardiovascular\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Zetia\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          612\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          702\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,314\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          568\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          635\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,202\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          633\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          691\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,526\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          11\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          9\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Vytorin\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          277\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          293\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          570\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          320\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          320\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          640\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          302\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          308\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,251\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -9\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -11\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          Diabetes\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Januvia\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          906\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,064\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,970\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          884\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,044\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,928\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,014\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          921\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3,863\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Janumet\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          506\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          569\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,075\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          509\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          554\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,063\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          562\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          526\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,151\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          General Medicine &amp; Women&#8217;s Health\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          NuvaRing\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          175\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          200\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          376\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          166\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          182\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          348\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          190\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          193\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          732\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          10\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          8\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Implanon \/ Nexplanon\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          164\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          298\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          137\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          124\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          261\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          176\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          151\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          588\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          32\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          14\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Dulera\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          113\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          121\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          234\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          130\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          120\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          251\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          133\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          153\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          536\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -7\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Follistim AQ\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          94\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          73\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          167\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          82\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          111\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          193\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          95\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          95\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          383\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -35\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -13\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">\n          <b>Hospital and Specialty<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          Hepatitis\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Zepatier\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          50\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          112\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          161\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignr\">\n          *\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignr\">\n          *\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          HIV\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Isentress\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          340\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          338\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          678\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          385\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          375\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          760\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          377\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          374\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,511\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -10\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -11\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          Hospital Acute Care\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Cubicin<sup>(2)<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          292\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          357\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          649\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          187\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          293\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          480\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          325\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          322\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,127\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          22\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          35\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Noxafil\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          145\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          143\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          288\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          111\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          117\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          228\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          132\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          128\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          487\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          22\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          26\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Cancidas\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          133\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          131\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          263\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          163\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          297\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          139\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          137\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          573\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -2\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -11\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Invanz\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          114\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          143\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          257\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          132\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          139\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          271\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          153\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          144\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          569\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          3\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -5\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Bridion\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          90\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          113\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          204\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          85\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          87\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          172\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          89\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          92\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          353\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          30\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          18\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Primaxin\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          73\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          81\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          154\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          65\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          88\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          153\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          75\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          86\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          313\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -8\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          Immunology\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Remicade\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          349\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          339\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          688\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          501\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          455\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          956\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          442\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          396\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,794\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -26\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -28\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Simponi\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          188\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          199\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          387\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          158\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          169\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          327\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          178\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          185\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          690\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          18\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          19\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">\n          <b>Oncology<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Keytruda\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          249\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          314\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          563\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          83\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          110\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          192\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          159\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          214\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          566\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignr\">\n          *\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignr\">\n          *\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Emend\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          126\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          143\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          268\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          122\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          134\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          255\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          141\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          139\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          535\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          7\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Temodar\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          66\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          73\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          139\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          74\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          80\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          155\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          83\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          75\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          312\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -9\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -10\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">\n          <b>Diversified Brands<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          Respiratory\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Singulair\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          237\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          229\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          465\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          245\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          212\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          457\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          201\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          273\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          931\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          8\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Nasonex\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          229\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          101\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          331\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          289\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          215\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          504\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          121\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          231\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          858\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -53\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -34\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6  bwvertalignt bwalignl\">\n          Other\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Cozaar \/ Hyzaar\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          126\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          132\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          258\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          185\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          189\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          374\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          150\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          143\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          667\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -30\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -31\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Arcoxia\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          111\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          117\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          228\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          123\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          115\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          238\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          123\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          110\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          471\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -4\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Fosamax\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          75\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          73\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          148\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          94\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          96\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          190\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          86\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          82\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          359\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -24\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -22\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Zocor\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          46\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          50\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          96\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          49\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          63\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          112\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          56\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          49\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          217\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -21\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -15\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">\n          <b>Vaccines<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Gardasil \/ Gardasil 9\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          378\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          393\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          770\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          359\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          427\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          785\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          625\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          497\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,908\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -8\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -2\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          ProQuad \/ M-M-R II \/ Varivax\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          357\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          383\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          739\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          348\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          358\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          705\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          390\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          409\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,505\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          7\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          RotaTeq\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          188\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          130\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          318\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          192\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          89\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          281\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          160\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          169\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          610\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          46\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          13\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Zostavax\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          125\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          149\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          274\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          175\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          149\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          324\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          179\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          246\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          749\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -15\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl8  bwvertalignt bwalignl\">\n          Pneumovax 23\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          107\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          120\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          228\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          110\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          106\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          216\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          138\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          188\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          542\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          14\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4  bwvertalignt bwalignl\">\n          <b>Other Pharmaceutical<\/b><br \/>\n<sup><br \/>\n<b>(3)<\/b><br \/>\n<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,093\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,151\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,246\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,235\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,274\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          2,512\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,298\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          1,300\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          5,105\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -9\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          -11\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2  bwvertalignt bwalignl\">\n          <b>ANIMAL HEALTH<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>829<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>898<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,727<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>829<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>840<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>1,669<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>825<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>830<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>3,324<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>7<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">\n          <b>4<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwpadb1  bwvertalignt bwalignl\">\n          <b>Other Revenues<\/b><br \/>\n<sup><br \/>\n<b>(4)<\/b><br \/>\n<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>379<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>246<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>625<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>330<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>381<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>711<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>323<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>358<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>1,392<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>-36<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n          <b>-12<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"2\">\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          * 100% or greater\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Sum of quarterly amounts may not equal year-to-date amounts due to<br \/>\n          rounding.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>(1)<\/sup> Only select products are shown.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>(2)<\/sup> First quarter of 2015 reflects approximately two<br \/>\n          months of sales following the acquisition of Cubist Pharmaceuticals,<br \/>\n          Inc. by Merck on January 21, 2015.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>(3)<\/sup> Includes Pharmaceutical products not individually<br \/>\n          shown above. Other Vaccines sales included in Other Pharmaceutical<br \/>\n          were $103 million in the first quarter and $91 million in the second<br \/>\n          quarter of 2016. Other Pharmaceutical sales were $78 million, $76<br \/>\n          million, $99 million and $148 million for the first, second, third<br \/>\n          and fourth quarters of 2015, respectively.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          <sup>(4)<\/sup> Other revenues are comprised primarily of alliance<br \/>\n          revenue, third-party manufacturing sales and miscellaneous corporate<br \/>\n          revenues, including revenue hedging activities.\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160729005318r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Lainie Keller, 908-236-5036<br \/>or<br \/>Investors:<br \/>Teri        Loxam, 908-740-1986<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS Was $0.93 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to $3.77 Advanced KEYTRUDA Development Program KEYTRUDA Demonstrated Superior Progression-Free Survival and Overall Survival Compared to Chemotherapy in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study Merck Received Positive Opinion from Committee for Medicinal Products for Human Use of the European Medicines Agency for KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in Patients Whose Tumors Express PD-L1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016. \u201cOur<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-745339","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Second-Quarter 2016 Financial Results - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Second-Quarter 2016 Financial Results - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS Was $0.93 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to $3.77 Advanced KEYTRUDA Development Program KEYTRUDA Demonstrated Superior Progression-Free Survival and Overall Survival Compared to Chemotherapy in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study Merck Received Positive Opinion from Committee for Medicinal Products for Human Use of the European Medicines Agency for KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in Patients Whose Tumors Express PD-L1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016. \u201cOur\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"20 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-second-quarter-2016-financial-results\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-second-quarter-2016-financial-results\\\/\",\"name\":\"Merck Announces Second-Quarter 2016 Financial Results - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-07-29T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:25:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-second-quarter-2016-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-second-quarter-2016-financial-results\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-second-quarter-2016-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Second-Quarter 2016 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Second-Quarter 2016 Financial Results - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Second-Quarter 2016 Financial Results - Merck.com","og_description":"Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS Was $0.93 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to $3.77 Advanced KEYTRUDA Development Program KEYTRUDA Demonstrated Superior Progression-Free Survival and Overall Survival Compared to Chemotherapy in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study Merck Received Positive Opinion from Committee for Medicinal Products for Human Use of the European Medicines Agency for KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in Patients Whose Tumors Express PD-L1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016. \u201cOur","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:42+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"20 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/","name":"Merck Announces Second-Quarter 2016 Financial Results - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-07-29T05:45:00+00:00","dateModified":"2025-11-07T06:25:42+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-second-quarter-2016-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Second-Quarter 2016 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"527781e6-6ad7-4eb5-95b4-8c706de4ad74","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2016\/07\/1\/merck_logo.jpg","size":"21167","File Upload":""}],"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745339\/revisions"}],"predecessor-version":[{"id":3674746,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745339\/revisions\/3674746"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745339"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}